Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2019-12-11
- Target Recruit Count
- 22
- Registration Number
- NCT00840931
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT00840827
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Lenalidomide In Patients With Acute Myeloid Leukemia
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 14
- Registration Number
- NCT00839059
- Locations
- 🇩🇪
University Hospital of Bonn, Bonn, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00837031
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00833534
Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 11
- Registration Number
- NCT00812968
- Locations
- 🇯🇵
Celgene Clinical Site, Shizuoka, Japan
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 48
- Registration Number
- NCT00799513
- Locations
- 🇮🇹
San Raffaele Scientific Institute, Milan, Italy
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00792077
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 63
- Registration Number
- NCT00790842
- Locations
- 🇺🇸
Metro MN CCOP, Saint Louis Park, Minnesota, United States
🇺🇸Emory University Winship Cancer, Atlanta, Georgia, United States
🇺🇸Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00784927
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.